Lyka Labs Ltd's Q3FY25 Quarter Results
- 05 Feb 2025
Result Summary
- Lyka Labs Ltd reported a 15.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 4.6%.
- Its expenses for the quarter were down by 19.4% QoQ and up 4.1% YoY.
- The net profit increased 29.0% QoQ and increased 34.8% YoY.
- The earnings per share (EPS) of Lyka Labs Ltd stood at 0.8 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 34.62 | 41.18 | 33.11 | -15.9% | 4.6% |
Total Expenses | 31.04 | 38.50 | 29.82 | -19.4% | 4.1% |
Profit Before Tax | 3.57 | 2.67 | 3.29 | 33.7% | 8.5% |
Tax | 0.87 | 0.76 | 1.27 | 14.5% | -31.5% |
Profit After Tax | 2.71 | 2.10 | 2.01 | 29.0% | 34.8% |
Earnings Per Share | 0.80 | 0.60 | 0.50 | 33.3% | 60.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Lyka Labs Ltd is a company that operates in the pharmaceutical sector. It is engaged in the development, manufacturing, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company has a diversified product portfolio that includes injectables, topical preparations, and other pharmaceutical products. As of the latest available information, there are no specific recent major developments or strategic shifts publicly mentioned for Lyka Labs Ltd. The company continues to contribute to the healthcare industry with its range of medicinal products, focusing on enhancing its market presence and operational efficiency.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Lyka Labs Ltd recorded a total income of ₹34.62 crores. This represents a decrease of 15.9% compared to the previous quarter (Q2FY25), where the total income was ₹41.18 crores. Despite the quarter-over-quarter decline, the year-over-year comparison shows a 4.6% increase from ₹33.11 crores in the third quarter of the fiscal year 2024 (Q3FY24). This data reflects the company's ability to maintain revenue growth on an annual basis, even though there was a noticeable drop in sequential quarterly revenue.
Profitability
For the third quarter of the fiscal year 2025, Lyka Labs Ltd reported a profit before tax of ₹3.57 crores, marking a 33.7% increase from the ₹2.67 crores reported in the previous quarter. Compared to the third quarter of the fiscal year 2024, there was an 8.5% increase from ₹3.29 crores. The tax expense for Q3FY25 was ₹0.87 crores, which increased by 14.5% quarter-over-quarter but decreased by 31.5% year-over-year. Consequently, the profit after tax for Q3FY25 was ₹2.71 crores, up 29.0% from ₹2.10 crores in Q2FY25, and 34.8% higher than ₹2.01 crores in Q3FY24. Earnings per share (EPS) for this quarter was ₹0.80, showcasing a 33.3% increase from the previous quarter and a notable 60.0% rise from the same quarter last year.
Operating Metrics
Lyka Labs Ltd's total expenses for Q3FY25 amounted to ₹31.04 crores, reflecting a 19.4% decrease from ₹38.50 crores in Q2FY25. When compared to the same quarter of the previous fiscal year, expenses rose by 4.1% from ₹29.82 crores. This reduction in quarterly expenses alongside the increase in annual expenses indicates a shift in operational efficiency or cost management strategies. The company has managed to improve its profitability metrics significantly on both a quarterly and annual basis, despite fluctuations in revenue and expenses. These changes in operating metrics highlight the company's financial strategies and management's efforts to optimize operational performance.
